← Back
Data updated: Jun 28, 2026
DAITO
Generics Pharmaceuticals
DAITO is a generic drug manufacturer with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
DAITO's Key Drugs
DAITO's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
DAITO's Recent FDA Approvals
New NDA/BLA approvals for DAITO over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DAITO's Therapeutic Areas
Disease areas where DAITO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DAITO Pipeline Snapshot
Active clinical trials for DAITO across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-08-07
- Latest
- 2026-05-27
- Applications
- 1